The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Open accessAbstract
Purpose: The National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial demonstrated that the addition of oxaliplatin to fluorouracil plus leucovorin (FULV) improved disease-free survival (DFS) in patients with stage II or III colon cancer. This analysis is the first publication of overall survival (OS) for the NSABP C-07 study. We updated DFS and examined both end points in clinically relevant patient subsets. Patients and Methods: Other studies have identified patients age 70 or older and those with stage II disease as patient subsets in which oxaliplatin may not be effective. We investigated toxicity as a driver of divergent outcomes in these subsets. Results: In all, 2,409 eligible patients with follow-up were randomly assigned to either FULV (FU 500 mg/m 2 by intravenous [IV] bolus weekly for 6 weeks; leucovorin 500 mg/m 2 IV weekly for 6 weeks of each 8-week cycle for three cycles) or FLOX (FULV plus oxaliplatin 85 mg/m 2 IV on days 1, 15, and 29 of each cycle). With 8 years median follow-up, OS was similar between treatment groups (hazard ratio [HR], 0.88; 95% CI, 0.75 to 1.02; P = .08). FLOX remained superior for DFS (HR, 0.82; 95% CI, 0.72 to 0.93; P = .002). The effect of oxaliplatin on OS did not differ by stage of disease (interaction P = .38 for OS; interaction P = 0.37 for DFS) but did vary by age for OS (younger than age 70 v 70+ interaction P = .039). There was a similar trend for DFS (interaction P = .073). Oxaliplatin significantly improved OS in patients younger than age 70 (HR, 0.80; 95% CI, 0.68 to 0.95; P = .013), but no positive effect was evident in older patients. Conclusion: Overall, the addition of oxaliplatin to FULV has not been proven to extend OS in this trial, but the DFS effect remained strong. Unplanned subset analyses suggest a significant OS effect of oxaliplatin in patients younger than age 70.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,277
Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056
Self-citationA Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., Shepherd, L. E., Seitz, J. F., & Francini, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010957 · Cited by 986
The asymptotic properties of nonparametric tests for comparing survival distributions
SCHOENFELD, D. (1981) · Biometrika · doi:10.1093/biomet/68.1.316 · Cited by 500
McCleary, N. J., Meyerhardt, J. A., Green, E., Yothers, G., de Gramont, A., Van Cutsem, E., O'Connell, M., Twelves, C. J., Saltz, L. B., Haller, D. G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6638 · Cited by 271
Self-citationMcCleary, N. A. J., Meyerhardt, J. A., Green, E. M., Yothers, G., de Gramont, A., Cutsem, E. V., O'Connell, M. J., Twelves, C. J., Saltz, L. B., Sargent, D. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4010 · Cited by 105
Self-citation
Cited by
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32319-0 · Cited by 4,974
Brenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,404
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.022 · Cited by 1,375
Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., Walpole, E. T., Finch-Jones, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70447-9 · Cited by 1,306
NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0021 · Cited by 806
Rödel, C., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R.-D., Ghadimi, M., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 726
André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4238 · Cited by 683
Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3616 · Cited by 668
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Cercek, A., Roxburgh, C. S. D., Strombom, P., Smith, J. J., Temple, L. K. F., Nash, G. M., Guillem, J. G., Paty, P. B., Yaeger, R., Stadler, Z. K., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0071 · Cited by 650
Breugom, A. J., Swets, M., Bosset, J.-F., Collette, L., Sainato, A., Cionini, L., Glynne-Jones, R., Counsell, N., Bastiaannet, E., van den Broek, C. B. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71199-4 · Cited by 574
Papamichael, D., Audisio, R. A., Glimelius, B., de Gramont, A., Glynne-Jones, R., Haller, D., Köhne, C.-H., Rostoft, S., Lemmens, V., Mitry, E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu253 · Cited by 471
5-fluorouracil and cardiotoxicity: a review
Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Herrmann, J., Lerman, A., & Grothey, A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918780140 · Cited by 433
Tournigand, C., André, T., Bonnetain, F., Chibaudel, B., Lledo, G., Hickish, T., Tabernero, J., Boni, C., Bachet, J.-B., Teixeira, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5645 · Cited by 389
Hong, Y. S., Nam, B.-H., Kim, K.-P., Kim, J. E., Park, S. J., Park, Y. S., Park, J. O., Kim, S. Y., Kim, T.-Y., Kim, J. H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70377-8 · Cited by 383
Böckelman, C., Engelmann, B. E., Kaprio, T., Hansen, T. F., & Glimelius, B. (2015) · Acta Oncologica · doi:10.3109/0284186x.2014.975839 · Cited by 367
Kerckhove, N., Collin, A., Condé, S., Chaleteix, C., Pezet, D., & Balayssac, D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00086 · Cited by 350
Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0213 · Cited by 343
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
Sinicrope, F. A., Shi, Q., Smyrk, T. C., Thibodeau, S. N., Dienstmann, R., Guinney, J., Bot, B. M., Tejpar, S., Delorenzi, M., Goldberg, R. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.041 · Cited by 330
Allegra, C. J., Yothers, G., O’Connell, M. J., Beart, R. W., Wozniak, T. F., Pitot, H. C., Shields, A. F., Landry, J. C., Ryan, D. P., Arora, A., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv248 · Cited by 326
Self-citationGavin, P. G., Colangelo, L. H., Fumagalli, D., Tanaka, N., Remillard, M. Y., Yothers, G., Kim, C., Taniyama, Y., Kim, S. I., Choi, H. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0605 · Cited by 320
Self-citationTaieb, J., Tabernero, J., Mini, E., Subtil, F., Folprecht, G., Van Laethem, J.-L., Thaler, J., Bridgewater, J., Petersen, L. N., Blons, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70227-x · Cited by 291
Schmoll, H.-J., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., Hill, M., Hoersch, S., Rittweger, K., & Haller, D. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9107 · Cited by 291
Sanoff, H. K., Carpenter, W. R., Stürmer, T., Goldberg, R. M., Martin, C. F., Fine, J. P., McCleary, N. J., Meyerhardt, J. A., Niland, J., Kahn, K. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.1140 · Cited by 271
Lin, C. C., Bruinooge, S. S., Kirkwood, M. K., Olsen, C., Jemal, A., Bajorin, D., Giordano, S. H., Goldstein, M., Guadagnolo, B. A., Kosty, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1558 · Cited by 263
Interpretable survival prediction for colorectal cancer using deep learning
Wulczyn, E., Steiner, D. F., Moran, M., Plass, M., Reihs, R., Tan, F., Flament-Auvigne, I., Brown, T., Regitnig, P., Chen, P.-H. C., et al. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00427-2 · Cited by 231
Malesci, A., Bianchi, P., Celesti, G., Basso, G., Marchesi, F., Grizzi, F., Di Caro, G., Cavalleri, T., Rimassa, L., Palmqvist, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342918 · Cited by 124
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0452 · Cited by 90
“Therefore, HER3-targeted therapies have been developed (24, 25); however, monoclonal antibody against HER3, such as patritumab, or dualtarget monoclonal antibodies against EGFR/HER3, such as duligotuzumab, have not shown any significant clinical benefit in mCRC patients in early clinical trials (26, 27).”
BackgroundMaking sense of adjuvant chemotherapy in colorectal cancer
Chan, G. H. J., & Chee, C. E. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.06.03 · Cited by 82
Adjuvant chemotherapy in resected colon cancer: When, how and how long?
Gelibter, A. J., Caponnetto, S., Urbano, F., Emiliani, A., Scagnoli, S., Sirgiovanni, G., Napoli, V. M., & Cortesi, E. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.06.003 · Cited by 75
Pathologist validation of a machine learning–derived feature for colon cancer risk stratification
L’Imperio, V., Wulczyn, E., Plass, M., Müller, H., Tamini, N., Gianotti, L., Zucchini, N., Reihs, R., Corrado, G. S., Webster, D. R., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.54891 · Cited by 57
Zunder, S. M., van Pelt, G. W., Gelderblom, H. J., Mancao, C., Putter, H., Tollenaar, R. A., & Mesker, W. E. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0083-0 · Cited by 36
Metadata
- Authors
- Yothers, G., O'Connell, M. J., Allegra, C. J., Kuebler, J. P., Colangelo, L. H., Petrelli, N. J., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-10-01
- Volume
- 29
- Issue
- 28
- Pages
- 3768-3774
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100258195
- Cited by
- 656
- References
- 12
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.